[Pulmonary diffusion test to NO and CO time course during thoracic radiotherapy for lung cancer: the CONORT prospective study protocol]
| Autor: | V, Zarza, S, Couraud, A, Hassouni, C, Prévost, P-J, Souquet, G, Letanche, Y, Hammou, N, Girard, C, Viart-Ferber, F, Mornex |
|---|---|
| Jazyk: | francouzština |
| Rok vydání: | 2014 |
| Předmět: |
Aged
80 and over Male Organs at Risk Carbon Monoxide Cell Membrane Permeability Lung Neoplasms Adenocarcinoma Middle Aged Nitric Oxide Radiosurgery Capillaries Plethysmography Pulmonary Alveoli Research Design Spirometry Colonic Neoplasms Humans Pulmonary Diffusing Capacity Female Prospective Studies Four-Dimensional Computed Tomography Aged |
| Zdroj: | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 18(5-6) |
| ISSN: | 1769-6658 |
| Popis: | Thoracic radiotherapy is a usual treatment for lung cancer. Early-stages may be treated in stereotactic mode while locally advanced stages are usually treated with conventional radiotherapy mode. Pulmonary function tests show that thoracic irradiation has no impact on lung volume such as forced expiratory volume in one second (FEV1) or forced vital capacity (FCV). However, some studies found that CO (carbon monoxide) diffusing capacity (TLCO) may be altered under thoracic radiotherapy. DLCO alteration is usually symptomatic of either a lesion in the alveolar membrane or a pulmonary capillary alteration. Pulmonary diffusion may be also appreciated by the NO (azote monoxide) diffusion capacity. Moreover, using a double measurement of NO and CO diffusing capacities permit to assess which lung compartment (capillary or membrane) is affected. CONORT is an observational prospective monocentric study, aiming to assess the CO and NO diffusing capacity (as well as other pulmonary function tests) during thoracic radiotherapy. Inclusion criteria are patients with lung cancer, treated by thoracic radiotherapy (conformational or stereotactic), who signed consent. Pulmonary function tests are performed before, during, at the end and six weeks and six months after thoracic irradiation. To estimate a difference of 15% in diffusing capacity test, we have to include 112 patients with a 90% power and a 5% alpha risk. Four months after beginning, 36 patients were included. Preliminary data will be presented at the SFRO meeting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect